Last reviewed · How we verify
PPP001
At a glance
| Generic name | PPP001 |
|---|---|
| Also known as | QIXLEEF |
| Sponsor | Tetra Bio-Pharma |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Inhaled Cannabis For the Uncontrolled Pain Relief in Patients With Advanced Cancer (PHASE2)
- Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain (PHASE2)
- Safety and Pharmacokinetics of Vaped Cannabis in Healthy Volunteers (PHASE1)
- Safety and Pharmacokinetics of Smoked Cannabis in Healthy Patients (PHASE1)
- Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPP001 CI brief — competitive landscape report
- PPP001 updates RSS · CI watch RSS
- Tetra Bio-Pharma portfolio CI